Waiting for JAK inhibitor safety data
Waiting for JAK inhibitor safety data
About this item
Full title
Author / Creator
Publisher
England: EULAR
Journal title
Language
English
Formats
Publication information
Publisher
England: EULAR
Subjects
More information
Scope and Contents
Contents
The US Food and Drug Administration (FDA) has recently added a new ‘black box warning’ on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of arthritis and other inflammatory conditions based on results from the ORAL Surveillance study of tofacitinib versus tumour necrosis factor alpha inhibitors in rheumatoid arthri...
Alternative Titles
Full title
Waiting for JAK inhibitor safety data
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_876e44beaa864f6e833b567ae77dd8f6
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_876e44beaa864f6e833b567ae77dd8f6
Other Identifiers
ISSN
2056-5933
E-ISSN
2056-5933
DOI
10.1136/rmdopen-2022-002236
